news
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
List view / Grid view
Anti-Cancer Therapeutics
news
Calquence fails to prevent respiratory failure in COVID-19 patients
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
news
Lenvima plus Keytruda achieves primary endpoints in trial for RCC
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
news
Using Th17 cells researchers make adoptive T-cell transfer therapy viable
Adoptive T-cell transfer therapy has had limited use due to the time involved in CD8+ T cell expansion, using a different type of T cell researchers were able to shorten this timeline, making the therapy more accessible.
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-300x278.jpg)
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-scaled-e1605009301887.jpg)
news
Merck to acquire VelosBio for $2.75 billion
The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.
news
NICE rules nivolumab is not cost effective for use on NHS
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
news
EC approves Zejula (niraparib) as a monotherapy for advanced ovarian cancer
The European Commission (EC) has approved Zejula, the first PARP-inhibitor monotherapy approved in the EU for patients with advanced ovarian cancer, regardless of their biomarker status.
news
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
news
FDA grants Orphan Drug Designation to two cancer treatments
The FDA has given small molecules APG-115 and APG-1252, two cancer treatments, Orphan Drug Designation.
news
Immunotherapies to treat cervical cancer show promise in Phase II trials
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
news
Avelumab significantly improves advanced bladder cancer patient survival
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
article
Single-cell analysis techniques: advances enabling early diagnosis of genetic diseases
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
news
MHRA issues positive opinion to avelumab for Early Access to Medicines Scheme
The UK MHRA has given a positive scientific opinion for Merck and Pfizer's avelumab on the Early Access to Medicines Scheme (EAMS).
news
Blenrep granted CMA for relapsed or refractory multiple myeloma
The European Commission granted the conditional marketing authorisation (CMA) based on data from a trial in which Blenrep achieved an overall response rate of 32 percent.
article
A novel cannabinoid formulation for glioblastoma treatment
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
